Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer - P&T Community

Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer P&T Community Small molecule and peptide therapies targeting PSMA, with various isotopes, have demonstrated serious off-target effects, such as pancreatitis, nephrotoxicity and permanent salivary gland ablation. These considerations are particularly important for ...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iTB9hZ
via IFTTT